Visikol differentiates itself through its expertise in advanced imaging and image analysis, 3D cell culture models and AI-enhanced digital pathology. The Visikol team has several patented and proprietary technologies for tissue imaging, tissue processing, and image analysis. Utilizing a suite of tools custom developed for image processing (known as 3Screen™), the Visikol team uses advanced automated and AI-enhanced image processing techniques to quantitatively analyze bioimaging data. We work closely with our Clients as an extension of their drug discovery team and work to develop customized research plans that best address their specific research question.
The inspiration for Visikol began at Rutgers University in the fall of 2012 when Visikol Co-Founder Dr. Tom Villani first developed the Visikol tissue clearing reagents for use with a wide range of tissues. These reagents have been used by hundreds of research groups from all around the world from the jungles of Rwanda, researchers in the Arctic Circle, to researchers at major research institutions such as La Jolla Institute for Allergy and Immunology, Cedars-Sinai, Harvard, University of Pennsylvania, and NIH. Today, Visikol has developed into a leading contract research services business that leverages its expertise in imaging, image analysis and advanced in vitro models to provide best-in-class services to its pharmaceutical and biotech Clients.